⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11630875 | 0.87 | — | — | |
| SCHEMBL2498264 | 0.76 | — | — | |
| SCHEMBL2732422 | 0.76 | — | — | |
| SCHEMBL2733472 | 0.76 | — | — | |
| SCHEMBL16097884 | 0.76 | — | — | |
| SCHEMBL11761205 | 0.75 | — | — | |
| SCHEMBL5468570 | 0.75 | — | — | |
| SCHEMBL21723218 | 0.73 | — | — | |
| SCHEMBL14469843 | 0.73 | — | — | |
| SCHEMBL77943 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278989-B1 | ORITAVANCIN FOR INHIBITING AND TREATING BIOFILMS | MELINTA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10201587-B2 | Methods of inhibiting and treating biofilms using glycopeptide antibiotics | MELINTA THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9220749-B2 | Method of inhibiting Clostridium difficile by administration of oritavancin | THE MEDICINES COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9089507-B2 | Use of oritavancin for prevention and treatment of anthrax | THE MEDICINES COMPANY (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2195004-B1 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN | MEDICINES CO (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20140100157-A1 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN | THE MEDICINES COMPANY (US) | 2014-04-10 | — | — | US | disclosed |
| US-20130310308-A1 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN | THE MEDICINES COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518873-B2 | Method of inhibiting clostridium difficile by administration of oritavancin | THE MEDICINES COMPANY (US) | 2013-08-27 | — | — | US | disclosed |
| CN-102316885-A | Method of inhibiting clostridium difficile by oritavancin administration | TARGANTA THERAPEUTICS CORP | 2012-01-11 | — | — | CN | disclosed |
| US-20110046041-A1 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS | TARGANTA THERAPEUTICS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| CN-1349407-A | Monthly dosing for treating streptococcal pneumonia infection | LILLY CO ELI (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1071334-C | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1031576-A2 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5843889-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1996030401-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| CN-1119649-A | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 1996-04-03 | — | — | CN | disclosed |
| EP-0667353-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |